APVO - CIK 0001671584
The table below shows Aptevo Therapeutics Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$25.59M | -$23.79M | -$11.73M | -$21.02M | -$21.68M | -$29.32M |
| Capital expenditure | - | - | - | $29.00K | $713.00K | $88.00K |
| Investing cash flow | $0.00 | $0.00 | $0.00 | -$29.00K | -$713.00K | $28.03M |
| Dividends paid | - | - | - | - | - |
Aptevo Therapeutics Inc. reported operating cash flow of -$25.59M for fiscal year 2025. That is down 7.6% from -$23.79M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow grew from -$41.57M (FY 2017) to -$25.59M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $38.50M | $15.60M | $6.00M | -$2.62M | $26.16M | $23.87M |